the ipledge program rems (risk evaluation and mitigation strategy) the ipledge program rems is a safety program to manage the risk of isotretinoin’s teratogenicity and to minimize fetal exposure. the rems is required by the u.s. food and drug administration (fda) to ensure the benefits of isotretinoin outweigh its risks.

we’re solving patient problems in a way where everyone wins. learn more about covermymeds.

an award-winning diagnostic clinical decision support system that enhances diagnostic accuracy, aids therapeutic decisions, and improves patient safety.

solutions to help life sciences organizations drive healthcare forward and get the right treatments to patients, faster.

welcome to dermnet, the world's leading free dermatology resource. scroll through evidence-based information on dermatological diseases (skin conditions), procedures, and treatments.

labcorp helps patients, providers, organizations, and biopharma companies to guide vital healthcare decisions each and every day.

providing accurate, impartial information on more than 24,000 prescription drugs and otc medications.